EcoDrugPlus

Dopamine Receptor D4b

Ensembl ID : ENSOSIG00000006605
Gene Symbol: DRD4B
1 Cross references
181 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSOSIG00000016926
Gene Symbol: ENPP2
1 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOSIG00000023652
Gene Symbol: EGLN1
1 Cross references
216 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSOSIG00000007615
Gene Symbol: EGLN2
1 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSOSIG00000008416
Gene Symbol: EGLN3
1 Cross references
198 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSOSIG00000017440
Gene Symbol: EPAS1B
1 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSOSIG00000012548
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:

Endothelin Receptor Type Ab

Ensembl ID : ENSOSIG00000016930
Gene Symbol: EDNRAB
1 Cross references
197 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSOSIG00000007752
Gene Symbol: EDNRB
1 Cross references
195 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSOSIG00000013117
Gene Symbol: EDNRB
1 Cross references
196 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSOSIG00000000170
Gene Symbol: EZH2
1 Cross references
229 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSOSIG00000004087
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).